Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients,Journal of Thoracic Oncology

当前位置： X-MOL 学术 › J. Thorac. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients
Journal of Thoracic Oncology ( IF 20.4 ) Pub Date : 2020-11-01 , DOI: 10.1016/j.jtho.2020.06.019
Christian Rolfo ₁ , Andrés F Cardona ₂ , Alejandro Ruiz-Patiño ₃ , Santiago Ariza ₄ , Lucia Zatarain-Barron ₅ , Luis E Pino ₆ , Lucia Viola ₇ , Alessandro Russo ₈ , Leonardo Rojas ₉ , Luisa Ricaurte ₁₀ , Oscar Arrieta ₅

Affiliation

Thoracic Oncology Unit, Marlene and Stewart Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia; Clinical and Traslational Oncology Group, Clínica del Country, Bogotá, Colombia.
Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
Dermatology Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.
Oncology Department, Institute of Oncology - Carlos Ardila Lülle Cancer Institute (ICAL), Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Thoracic Oncology Unit, Fundación Neumológica Colombiana - FNM, Bogotá, Colombia.
Thoracic Oncology Unit, Marlene and Stewart Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland; Medical Oncology Unit, A.O. Papardo, Messina, Italy.
Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia; Clinical and Traslational Oncology Group, Clínica del Country, Bogotá, Colombia; Clínical Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
Pathology Department, Mayo Clinic, Rochester, Minnesota.

Abstract A new coronavirus, named SARS-CoV-2 by the World Health Organization (WHO), has rapidly spread around the world since its first reported case in late December of 2019 from Wuhan, China. As of mid-April 2020, this virus has affected more than 180 countries and territories, infecting more than 1,650,000 individuals and causing over 100.000 deaths. With ≈20 million new cases per year globally, cancer affects a significant portion of the population. Individuals affected by cancer are more susceptible to infections due to coexisting chronic diseases (cardiovascular, pulmonary and diabetes), overall poor health status, and systemic immunosuppressive states caused by both cancer and anticancer treatments. As a consequence, patients with malignancies, and especially with lung cancer who develop COVID19 experience more difficult outcomes. A recent multicenter study developed by the Hubei Anti-Cancer Association also documented that lung cancer patients had an increased risk of death, ICU requirement, risk of presenting severe or critical symptoms, and use of invasive mechanical ventilation. Here we present two representative cases of patients with lung cancer and COVID19 without respiratory compromise and with atypical and severe skin manifestations, findings that could be influenced by the chronic use of anti-PD1 antibodies.

更新日期：2020-11-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>